Physician profile
Mirza Baig
NPI 1376906917
$2,777.56
in general payments reported to CMS, 2019-2025
14 companies · $359 in 2025
The $359 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $47.10 · 2021: $99.99 · 2022: $409 · 2023: $104 · 2024: $1,759 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,467 · Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,467.49 |
| Food and Beverage | $754.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,735.70 | 2022-2024 | Mitraclip |
| Amgen INC. | $246.10 | 2022-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $129.09 | 2022-2025 | Farapulse |
| E.R. Squibb & Sons, L.L.C. | $121.97 | 2023-2025 | Eliquis, Camzyos |
| Heartflow, INC. | $105.32 | 2024 | |
| Astellas Pharma US INC | $99.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $97.22 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.01 | 2020-2025 | Lifevest |
| Novo Nordisk INC | $48.72 | 2025 | Wegovy |
| Terumo Medical Corporation | $32.92 | 2025 | Azur Cx Detachable |
| Pfizer INC. | $27.84 | 2025 | |
| Cvrx, INC. | $27.54 | 2025 | Barostim Neo System |
| Esperion Therapeutics, INC. | $22.35 | 2024 | Nexletol |
| Edwards Lifesciences Corporation | $21.79 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mirza Baig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.